StockNews.com Begins Coverage on Cara Therapeutics (NASDAQ:CARA)

StockNews.com began coverage on shares of Cara Therapeutics (NASDAQ:CARAFree Report) in a research report released on Saturday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Cara Therapeutics Stock Performance

NASDAQ CARA opened at $0.26 on Friday. The company has a market cap of $14.00 million, a P/E ratio of -0.11 and a beta of 0.70. The business’s 50 day moving average price is $0.31 and its 200-day moving average price is $0.48. Cara Therapeutics has a fifty-two week low of $0.24 and a fifty-two week high of $1.65.

Cara Therapeutics (NASDAQ:CARAGet Free Report) last announced its earnings results on Wednesday, August 14th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.10). Cara Therapeutics had a negative net margin of 1,010.20% and a negative return on equity of 241.31%. The firm had revenue of $0.99 million during the quarter, compared to analysts’ expectations of $1.26 million. As a group, equities analysts predict that Cara Therapeutics will post -1.24 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Cara Therapeutics stock. Marquette Asset Management LLC acquired a new stake in Cara Therapeutics, Inc. (NASDAQ:CARAFree Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 94,238 shares of the biopharmaceutical company’s stock, valued at approximately $86,000. Marquette Asset Management LLC owned about 0.17% of Cara Therapeutics as of its most recent SEC filing. 44.66% of the stock is currently owned by institutional investors.

About Cara Therapeutics

(Get Free Report)

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.

Read More

Analyst Recommendations for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.